Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
1,2,3-triazole
100%
1H-1,2,3-triazole
50%
Antifungal Activity
50%
Antimicrobial Activity
100%
Aspergillus Niger
50%
Bacterial Infection
50%
Cellular Damage
50%
Cellular Stress
50%
Chemical Mixtures
100%
Chloramphenicol
50%
Clinical Signs
50%
Clinical Trials
50%
Copper-catalyzed Azide-alkyne Cycloaddition (CuAAC)
50%
Cytotoxicity
50%
Cytotoxicity Profile
50%
Degenerative Disease
100%
Disease Progression
50%
DNA Damage
50%
Drug Development
100%
Early Biomarker
100%
ESKAPE Pathogens
100%
Fungal Infection
50%
Gram-negative Bacteria
50%
Histological Analysis
50%
HMOX1
50%
In Vivo Reporter
50%
Indole
100%
Inflammation
50%
Knoevenagel Condensation
50%
Methyl
100%
Methylene
50%
MIC Values
50%
Multidrug-resistant
100%
Neurodegenerative Diseases
50%
Nuclear Factor Erythroid 2-related Factor 2 (Nrf2)
100%
Oxidative Stress
50%
P53 Pathway
50%
Pyrazole-3-one
50%
Pyrazolone
100%
Recent Advances
50%
Reporter Expression
100%
Reporter Mice
50%
Specific Mechanisms
50%
Synthesized Compounds
100%
TAR DNA-binding Protein 43 (TDP-43)
100%
Therapeutic Intervention
50%
Tolerability
50%
Transcription Profile
100%
Transgenerational Effects
100%
Vehicle Control
50%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter Baumannii
50%
Alkyne
50%
Ampicillin
50%
Amyotrophic Lateral Sclerosis
100%
Antifungal Activity
50%
Antiinfective Agent
100%
Antimicrobial Agent
50%
Aroclor 1254
100%
Aromatic Hydrocarbon Receptor
25%
Aspergillus Niger
50%
Azide
50%
Bacterial Infection
50%
Biological Marker
40%
Blood-Brain Barrier
40%
Candida Albicans
50%
Carbene
50%
Carcinogenesis
25%
Chloramphenicol
50%
Clinical Study
100%
Clinical Trial
40%
Cytoprotective Agent
40%
Cytotoxicity
100%
Degenerative Disease
40%
Disease Exacerbation
20%
Drug Development
100%
Fluconazole
50%
Glioblastoma
100%
Gram Negative Bacterium
50%
Immunotherapy
20%
Indole
100%
Infectious Agent
100%
Inflammation
45%
Maternal Exposure
25%
Mycosis
50%
Nystatin
50%
Overall Survival
20%
Polychlorinated Biphenyl
25%
Preclinical Study
100%
Progression Free Survival
20%
Protein P53
40%
Pyrazole
50%
Pyrazolone
100%
Randomized Controlled Trial
20%
Temozolomide
20%
Tolerability
50%
Transcription Factor Nrf2
25%
Transcriptome
25%
Triazole
100%
Tumor Growth
20%
Xenobiotic Metabolism
25%
Medicine and Dentistry
Adverse Event
14%
Blood Brain Barrier
28%
Cancer Inhibition
14%
Chemotherapy
14%
Clinical Study
100%
Clinical Trial
14%
Glioblastoma
100%
High-Intensity Focused Ultrasound
100%
Immunotherapy
14%
Intracranial Tumor
14%
Nanoparticle
14%
Overall Survival
14%
Progression Free Survival
14%
Punctate Hemorrhage
14%
Randomized Controlled Trial
14%
Recurrence Risk
14%
Study Heterogeneity
14%
Systematic Review
100%
Temozolomide
14%
Tumor
28%
Tumor Progression
14%
